Abivax announces ABTECT 1, ABTECT 2 trials met primary endpoint

Abivax (ABVX) SA announced results from the first of two late-breaking presentations at the United European Gastroenterology, UEG, Meeting in Berlin, Germany. The presentation includes results from Abivax’s Phase 3 ABTECT 8-Week Induction Trials investigating obefazimod for the treatment of moderate-to-severely active ulcerative colitis, including previously reported findings and additional safety data at week 8. Results from the ABTECT-1 and ABTECT-2 trials demonstrated that obefazimod met its FDA primary endpoint of clinical remission at Week 8 in the 50 mg once-daily dose regimen for both trials. Individually, ABTECT-1 showed a placebo-adjusted clinical remission rate of 19.3% and ABTECT-2 demonstrated 13.4%, each at the 50 mg once-daily dose, with all key secondary efficacy endpoints being met.